MicroPort® Attends 24th Cardiovascular Summit TCTAP 2019 in Korea

Seoul, South Korea – From April 27 to 30, the 24th Cardiovascular Summit TCTAP 2019 was held at the COEX Convention & Exhibition Center of Seoul, South Korea, bringing together healthcare professionals in the areas of cardiology, radiology and vascular surgery from across the world. Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) sponsored the satellite conference of “My Clinical Experience with MicroPort® Latest Technology” to host themed lectures and case presentations to share and discuss with the healthcare professionals in attendance the clinical experiences on Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). The other cutting-edge medical technologies of MicroPort® presented at the event were VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®"), which was close to launch, and Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System (“Firesorb®”), which was still under development.

On April 28, the satellite conference of “My Clinical Experience with MicroPort® Latest Technology” was co-chaired by Prof. Seung-Jea Tahk from Ajou University Hospital and Prof. Myung-Ho Jeong from Chonnam National University Hospital. Prof. Yong Cheol Kim from Chonnam National University Hospital, Prof. Ai-Hsien Li from Far Eastern Memorial Hospital and Dr. Chunpo from General Hospital of Tianjin Medical University spoke of the clinical application of Firehawk® in the treatment of complex coronary artery lesions in South Korea, Taiwan and Mainland China respectively. The two chairpersons had a heated discussion with the three speakers as well as the audience. The design and clinical results of Firehawk® were well received by the healthcare professionals in attendance.

In the next session, Prof. Bill D. Gogas from Nanjing First Hospital introduced the design rationale, the features and the latest outcomes of the pre-marketing clinical trial for Firesorb®, which is a second generation bioresorbable vascular stent system and independently developed by MicroPort®. Several healthcare professionals commented that Firesorb® had a good prospect for clinical application and would benefit more patients in the future. Prof. Bin Wang from Xiamen Cardiovascular Hospital Xiamen University spoke of the design rationale and clinical application of Vitaflow®, which was close to launch. His introduction of Vitaflow® II, which is the next generation of Vitaflow®, also attracted the attention and expectation from the audience.

As one of the most important markets in the Asia-Pacific region, South Korea provides a promising outlook for medical devices. MicroPort® has boosted its exploration of the South Korean market by showcasing the Firehawk® clinical applications in Asia-Pacific region and presenting the bioresorbable vascular stent system and transcatheter aortic valve replacement at TCTAP 2019. In the future, MicroPort® will commit to introducing more high-quality and high-end medical device products and services to South Korea and providing more comprehensive therapeutic solutions for local patients.